BBA
TMBR

Baker Bros. Advisors’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Baker Bros. Advisors’s Portfolio TMBR Stock Details TMBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-40
Closed -$171K – 125
2017
Q3 		$171K Hold
40
– – ﹤0.01% 118
2017
Q2 		$287K Buy
40
+15
+60% +$131K ﹤0.01% 116
2017
Q1 		$191K Buy
+25
New +$173K ﹤0.01% 117

Other funds holding TMBR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Baker Bros. Advisors's TMBR Position: Q4 2017 in Review

Baker Bros. Advisors sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q4 2017, closing a stake of 40 shares — an estimated $171K sold.

Baker Bros. Advisors first reported a position in TMBR in Q1 2017 and held it in 3 quarters. The position peaked at $287K in Q2 2017. 15 funds tracked by Wall St. Rank hold TMBR as of Q4 2017.

  • Baker Bros. Advisors reported no remaining Timber Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Baker Bros. Advisors sold 40 Timber Pharmaceuticals, Inc. shares in Q4 2017, an estimated $171K.
  • Baker Bros. Advisors first reported a position in Timber Pharmaceuticals, Inc. in Q1 2017 and held it in 3 quarters.
  • Baker Bros. Advisors's Timber Pharmaceuticals, Inc. position peaked at $287K in Q2 2017.
  • 15 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q4 2017.

Based on Baker Bros. Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.